Drug Trial Radar · NCT04083599
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
350
Actual
Start
Sep 17, 2019
Primary completion
Dec 30, 2025
Study completion Jan 2027
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- Collaborators
- BioNTech SE
- First posted
- Sep 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of participants with certain types of cancer.
Conditions
- Malignant Solid Tumor
- Non-Small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Melanoma
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
GEN1042Biological
Intravenous
PembrolizumabDrug
Intravenous
CisplatinDrug
Intravenous
CarboplatinDrug
Intravenous
5-FUDrug
Intravenous
GemcitabineDrug
Intravenous
Nab paclitaxelDrug
Intravenous
PemetrexedDrug
Intravenous
PaclitaxelDrug
Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation and Safety Run-in Parts: Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: First Cycle (21 days)
- Dose Expansion: Objective Response Rate (ORR)Time frame: Up to approximately 2 years and 4 months
Locations
76 sites in 12 countries. Site status is shown where the registry gives one.
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Cancer & Blood Specialty Clinic
Los Alamitos, California
Moores Cancer Center at the UC San Diego Health
San Diego, California
Yale University Cancer Center
New Haven, Connecticut
ChristianaCare
Newark, Delaware
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
Florida Cancer Affiliates
Ocala, Florida
Hope and Healing Cancer Services
Hinsdale, Illinois
University of Kentucky
Lexington, Kentucky
Norton Cancer Institute
Louisville, Kentucky
Maryland Oncology Hematology PA
Columbia, Maryland
Washington University School of Medicine
St Louis, Missouri
Levine Cancer Center
Charlotte, North Carolina
Novant Health Cancer Institute - Forsyth (Medical Oncology)
Winston-Salem, North Carolina
Kaiser Permanente (KP) Oncology/Hematology
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Sarah Cannon Research Institute
Nashville, Tennessee
Lumi Research
Kingwood, Texas
Utah Cancer Specialists
Salt Lake City, Utah
Virgina Cancer Specialists
Fairfax, Virginia
Adventist Health System/Sunbelt,Inc
Seattle, Washington
Medical Oncology Associates, PS
Spokane, Washington
Rigshospitalet (Copenhagen University Hospital)
Copenhagen, Denmark
Herlev University Hospital
Herlev, Denmark
University Hospital of Southern Denmark, Vejle Hospital
Vejle, Denmark
Centre hospitalier Universitaire de Bordeaux
Bordeaux, France
Centre Antoine Lacassagne
Nice, France
Gustave Roussy
Villejuif, France
ARENSIA Research Clinic at the Research Institute of Clinical Medicine
Tbilisi, Georgia
Nationales Centrum fr Tumorerkrankungen NCT
Heidelberg, Germany
Klinikum der Stadt Ludwigshafen am Rhein gGmbH
Ludwigshafen, Germany
Department of Dermatology, University of Mainz
Mainz, Germany
Universitätsmedizin Mannheim Dermatologie
Mannheim, Germany
Universitaetsklinikum Wuerzburg
Würzburg, Germany
Rabin Medical Center
Petah Tikva, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Azienda Ospedaliera Spedali Civili di Brescia
Brescia, Italy
Azienda Ospedaliera S.Croce e Carle Cuneo
Cuneo, Italy
Istituto Nazionale dei Tumori
Milan, Italy
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.